A rare disease, as defined by the FDA under the Orphan Drug Act, affects fewer than 200,000 people in the United States. Globally, estimates suggest more than 7,000 rare diseases have been identified, many of them serious, debilitating, genetic, and life-threatening. While each condition impacts a relatively small population, the collective burden is significant.
For patients and families, that burden extends beyond physical symptoms. Delayed diagnoses, limited treatment options, and uncertainty around disease progression contribute to a substantial psychological and emotional toll.
Clinical trials are often the only treatment option for rare disease patients. Against this backdrop, rare disease clinical trials present a distinct set of challenges, but also a clear opportunity to rethink how studies are designed. Clinical research in rare diseases must navigate small patient populations with limited enrollment, sparse or lack of natural history data, which lead to difficulty determining clinically meaningful endpoints during clinical trial design. Getting this right requires balancing scientific rigor with real-world feasibility, particularly in patient recruitment and endpoint selection.
Patient recruitment remains one of the most significant barriers in rare disease clinical trials.
Small, geographically dispersed populations make it difficult to identify and enroll eligible participants, often extending study timelines. In many cases, patients remain undiagnosed or misdiagnosed for years, further limiting the available pool.
Even when patients are identified, participation may be constrained by:
Addressing these challenges can include utilizing patient-centric and/or decentralized clinical trial models, such as home health monitoring/telemedicine. Getting this right means moving beyond traditional site-based approaches and designing recruitment strategies that meet patients where they are.
Limited natural history data, unclear disease progression, and the absence of standardized endpoints make it difficult to define what success looks like in a clinical trial.
To move forward, study teams rely on a combination of:
While data availability is improving, uncertainty remains a core challenge, particularly in early-stage development.
For many rare diseases, treatment options are limited or unavailable.
Patients often rely on symptom management and supportive care rather than therapies that address the underlying cause of the disease.
Even when treatments exist, access can be restricted by cost and availability. These realities must be considered during trial design. Trials that account for these constraints upfront are more likely to be both executable and relevant to patient needs.
Historically, rare disease research faced limited investment due to small market size.
That dynamic has changed.
Regulatory incentives, including orphan drug designation, accelerated approval pathways, and market exclusivity, have helped drive increased interest and funding in rare disease clinical research.
As a result, more therapies are moving through development, creating opportunities for more adaptive and innovative trial designs that better reflect the realities of rare disease populations.
Patient advocacy groups are central to progress in rare disease research.
In addition to raising awareness, these organizations:
Their collaboration with sponsors and clinical teams helps ensure that trials are designed with patient needs in mind.
However, in some cases, particularly in ultra-rare diseases, no formal patient advocacy group exists. In these situations, clinical trial teams must build this infrastructure from the ground up. This often involves partnering with key opinion leaders (KOLs) and rare disease specialists who can help identify and connect with patients, enabling direct interviews and the formation of early patient networks.
Biotech companies may also need to develop natural history registries to better understand disease progression and inform trial design.
Patient-centric approaches, such as incorporating feedback from patient advisory groups, are increasingly important for improving participation, retention, and overall study success. Incorporating these perspectives early can significantly improve both trial feasibility and outcomes.
Getting rare disease clinical trials right requires a different approach than traditional studies.
In practice, this depends on:
As methodologies evolve, there is growing opportunity to improve both the efficiency and effectiveness of rare disease clinical research, bringing meaningful therapies to patients who have historically had limited options.